888 related articles for article (PubMed ID: 29932212)
1. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
2. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
Wang B; Wen L; Wang Z; Chen S; Qiu H
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11.
Ishikawa Y; Kawashima N; Atsuta Y; Sugiura I; Sawa M; Dobashi N; Yokoyama H; Doki N; Tomita A; Kiguchi T; Koh S; Kanamori H; Iriyama N; Kohno A; Moriuchi Y; Asada N; Hirano D; Togitani K; Sakura T; Hagihara M; Tomikawa T; Yokoyama Y; Asou N; Ohtake S; Matsumura I; Miyazaki Y; Naoe T; Kiyoi H
Blood Adv; 2020 Jan; 4(1):66-75. PubMed ID: 31899799
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of CCAAT/Enhancer Binding Protein (C/EBP) Alpha (CEBPA) and Runt-Related Transcription Factor 1 (RUNX1) Expression in Patients with De Novo Acute Myeloid Leukemia.
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Farsani MA
Ann Hum Genet; 2017 Nov; 81(6):276-283. PubMed ID: 28895127
[TBL] [Abstract][Full Text] [Related]
6. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
7. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
[TBL] [Abstract][Full Text] [Related]
8. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
[TBL] [Abstract][Full Text] [Related]
9. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
10. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.
Skokowa J; Steinemann D; Katsman-Kuipers JE; Zeidler C; Klimenkova O; Klimiankou M; Unalan M; Kandabarau S; Makaryan V; Beekman R; Behrens K; Stocking C; Obenauer J; Schnittger S; Kohlmann A; Valkhof MG; Hoogenboezem R; Göhring G; Reinhardt D; Schlegelberger B; Stanulla M; Vandenberghe P; Donadieu J; Zwaan CM; Touw IP; van den Heuvel-Eibrink MM; Dale DC; Welte K
Blood; 2014 Apr; 123(14):2229-37. PubMed ID: 24523240
[TBL] [Abstract][Full Text] [Related]
11. Reclassification of Acute Myeloid Leukemia According to the 2016 WHO Classification.
Jung J; Cho BS; Kim HJ; Han E; Jang W; Han K; Lee JW; Chung NG; Cho B; Kim M; Kim Y
Ann Lab Med; 2019 May; 39(3):311-316. PubMed ID: 30623623
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
[TBL] [Abstract][Full Text] [Related]
14. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
[No Abstract] [Full Text] [Related]
15. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
Fasan A; Alpermann T; Haferlach C; Grossmann V; Roller A; Kohlmann A; Eder C; Kern W; Haferlach T; Schnittger S
PLoS One; 2013; 8(2):e54365. PubMed ID: 23383300
[TBL] [Abstract][Full Text] [Related]
16. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
Ommen HB; Schnittger S; Jovanovic JV; Ommen IB; Hasle H; Østergaard M; Grimwade D; Hokland P
Blood; 2010 Jan; 115(2):198-205. PubMed ID: 19901261
[TBL] [Abstract][Full Text] [Related]
17. Companion gene mutations and their clinical significance in AML with double mutant CEBPA.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Teng W; Cao P; Nie D; Ma X; Wang T; Lu P; Liu H
Cancer Gene Ther; 2020 Aug; 27(7-8):599-606. PubMed ID: 31477806
[TBL] [Abstract][Full Text] [Related]
18. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
19. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
[No Abstract] [Full Text] [Related]
20. Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating Factor.
Abe A; Yamamoto Y; Katsumi A; Yamamoto H; Okamoto A; Inaguma Y; Iriyama C; Tokuda M; Okamoto M; Emi N; Tomita A
Cytogenet Genome Res; 2020; 160(5):255-263. PubMed ID: 32544910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
